[go: up one dir, main page]

CO2017008087A2 - Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modo - Google Patents

Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modo

Info

Publication number
CO2017008087A2
CO2017008087A2 CONC2017/0008087A CO2017008087A CO2017008087A2 CO 2017008087 A2 CO2017008087 A2 CO 2017008087A2 CO 2017008087 A CO2017008087 A CO 2017008087A CO 2017008087 A2 CO2017008087 A2 CO 2017008087A2
Authority
CO
Colombia
Prior art keywords
recombinant
protein
cell clones
free medium
antibody
Prior art date
Application number
CONC2017/0008087A
Other languages
English (en)
Inventor
Meylen Chea
Julio Palacios
Miguel Arias
Loany Calvo
Tamara Gonzalez
Rolando Perez
zhi Bai
Yuemao Liu
Kaiheng Xiao
Xiao Chen
Zhenhua He
Yangliu Cai
Zhenhua Yang
Xianhong Bai
Original Assignee
Biotech Pharmaceutical Co Ltd
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Pharmaceutical Co Ltd, Ct Inmunologia Molecular filed Critical Biotech Pharmaceutical Co Ltd
Publication of CO2017008087A2 publication Critical patent/CO2017008087A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para recuperar clones de células de mieloma recombinante adaptadas para crecer en medios libres de proteínas. Este procedimiento comprende líneas de células de mieloma recombinante para las que el proceso de adaptación de medio libre de suero a medio libre de proteína no es posible o toma mucho tiempo y se acompaña de la pérdida de producción de anticuerpos debido a la aparición de poblaciones de células no productoras. Los procedimientos incluyen un proceso de adaptación gradual para crecer en medio libre de proteínas a baja y alta densidad celular. La adaptación fenotípica para crecer en medio libre de proteínas a alta densidad celular fue acompañada por un aumento en la velocidad de secreción de la molécula de anticuerpo recombinante y en el porcentaje de clones de células productoras estables. Los clones celulares revelados en la presente invención producen el anticuerpo recombinante humanizado Anti - NeuGcGM3 14F7h. Además, los atributos de identidad de dicho anticuerpo recombinante humanizado anti-NeuGcGM3 14F7 se describen en esta invención.
CONC2017/0008087A 2015-02-14 2017-08-10 Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modo CO2017008087A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510080631.3A CN104651314B (zh) 2015-02-14 2015-02-14 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
PCT/CN2016/076135 WO2016127954A1 (zh) 2015-02-14 2016-03-11 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子

Publications (1)

Publication Number Publication Date
CO2017008087A2 true CO2017008087A2 (es) 2017-10-10

Family

ID=53242962

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0008087A CO2017008087A2 (es) 2015-02-14 2017-08-10 Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modo

Country Status (17)

Country Link
US (1) US10457747B2 (es)
JP (1) JP2018506306A (es)
KR (1) KR20180029948A (es)
CN (1) CN104651314B (es)
AU (1) AU2016218641C1 (es)
BR (1) BR112017017303B8 (es)
CA (1) CA2974027C (es)
CO (1) CO2017008087A2 (es)
CU (1) CU20170106A7 (es)
EA (1) EA201791828A1 (es)
IL (1) IL253932A0 (es)
MX (1) MX384316B (es)
MY (1) MY192147A (es)
NZ (1) NZ735485A (es)
SG (1) SG11201706595TA (es)
TN (1) TN2017000302A1 (es)
WO (1) WO2016127954A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104651314B (zh) 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
EP3257935A4 (en) * 2016-03-11 2018-08-08 Biotech Pharmaceutical Co. Ltd. Method for obtaining high-yield, stable-expression cell clones and antibody molecules obtained thereby
CN113480652B (zh) * 2021-07-30 2023-04-07 成都景泽生物制药有限公司 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
CU23097A1 (es) * 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005042768A2 (en) * 2003-11-03 2005-05-12 Centocor, Inc. Method for maintaining low shear in a bioprocessing system
CU24120B1 (es) * 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
CN104152415B (zh) * 2014-08-13 2015-09-30 百泰生物药业有限公司 获得高产稳定表达重组抗体的骨髓瘤细胞株的方法及应用
CN104651314B (zh) * 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子

Also Published As

Publication number Publication date
MY192147A (en) 2022-08-01
NZ735485A (en) 2019-08-30
AU2016218641C1 (en) 2020-02-27
EA201791828A1 (ru) 2017-12-29
BR112017017303B1 (pt) 2023-08-08
CA2974027C (en) 2021-02-16
AU2016218641A1 (en) 2017-10-05
CA2974027A1 (en) 2016-08-18
AU2016218641B2 (en) 2019-10-31
MX384316B (es) 2025-03-14
CN104651314B (zh) 2018-06-19
CN104651314A (zh) 2015-05-27
BR112017017303B8 (pt) 2024-03-05
MX2017010421A (es) 2018-04-26
US10457747B2 (en) 2019-10-29
JP2018506306A (ja) 2018-03-08
US20180016353A1 (en) 2018-01-18
SG11201706595TA (en) 2017-09-28
IL253932A0 (en) 2017-10-31
TN2017000302A1 (en) 2019-01-16
KR20180029948A (ko) 2018-03-21
BR112017017303A2 (pt) 2018-04-10
WO2016127954A1 (zh) 2016-08-18
CU20170106A7 (es) 2018-06-05

Similar Documents

Publication Publication Date Title
AR132934A2 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
BR112021011298A2 (pt) Produção de 3-fucosillactose e lactose por conversão de enzimas alfa-1,3-fucosiltransferase
CL2019002521A1 (es) Método para producir anticuerpos multiespecíficos.
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
CO2017008087A2 (es) Método para obtener clones celulares de expresión estable de alto rendimiento y moléculas de anticuerpos obtenidas de este modo
AR088252A1 (es) Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris
BR112015023036A2 (pt) método para preparar um produto alcaloide benzilisoquinolina e célula microbiana engenheirada que produz um produto alcaloide benzilisoquinolina
IN2013MU02285A (es)
EP4446338A3 (en) Cells and method of cell culture
BR112014026308A2 (pt) composições de cultura celular e métodos para produção de polipeptídeos
MX2012012496A (es) Metodo para producir tetrafluoropropenos.
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
MX391041B (es) Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
BR112021024852A2 (pt) Métodos de cultura de célula e composições para produção de anticorpo
MX381844B (es) Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos
CO2022007349A2 (es) Métodos para producir células de epitelio pigmentario retiniano
MX2020001920A (es) Metodos de inactivacion de contaminantes virales.
AR097805A1 (es) Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados
SG11202009826PA (en) Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells
BR112022009152A2 (pt) Processo de fabricação para preparar células t expressando receptores de antígenos quiméricos
MX2013009598A (es) Composiciones que comprenden alquilalcoxisulfonatos para la produccion de espumas estables a alta temperatura.
ZA202201894B (en) Method for in vitro production of hyaline cartilage tissue
CO6761370A2 (es) Arn interferentespequeños con secuencias seminales con diana especifica
CO2023018294A2 (es) Métodos de nmr para la comparabilidad de estructuras de orden superior de anticuerpos
EA201791423A1 (ru) Способ получения белка